Cargando…
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis
BACKGROUND & AIMS: Patients with Crohn’s disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and resp...
Autores principales: | Faleck, David M., Winters, Adam, Chablaney, Shreya, Shashi, Preeti, Meserve, Joseph, Weiss, Aaron, Aniwan, Satimai, Koliani-Pace, Jenna L., Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Kesar, Varun, Lasch, Karen, Luo, Michelle, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Hudesman, David, Chang, Shannon, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Siegel, Corey A., Shen, Bo, Sandborn, William J., Kane, Sunanda, Loftus, Edward V., Sands, Bruce E., Colombel, Jean-Frederic, Dulai, Parambir S., Ungaro, Ryan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026826/ https://www.ncbi.nlm.nih.gov/pubmed/30625408 http://dx.doi.org/10.1016/j.cgh.2018.12.040 |
Ejemplares similares
-
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
por: Koliani-Pace, Jenna L, et al.
Publicado: (2019) -
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis
por: Lukin, Dana, et al.
Publicado: (2020) -
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
por: Dulai, Parambir S., et al.
Publicado: (2020) -
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020) -
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
por: Narula, Neeraj, et al.
Publicado: (2019)